COVID-19 Severity in Multiple SclerosisMaria Pia Sormani, Giovanna Borriello, Paolo Confalonieri et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 74
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)Silvia Messina, Claudio Solaro, Isabella Righini et al.|PLoS ONE|2017Cited by 58
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort studyMaria Pia Sormani, Laura Brambilla, Irene Schiavetti et al.|Multiple Sclerosis Journal|2021Cited by 52
A real‐world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Alessio Signori, Francesco Saccà et al.|European Journal of Neurology|2021Cited by 26
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Alessio Signori, Giacomo Lus et al.|Multiple Sclerosis Journal|2021Cited by 19